Differences in Pharmacokinetics and Pharmacodynamics of Insulin Lispro and Aspart in Healthy Volunteers

 

 Buy Article Permissions and Reprints

Summary

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 ± 0.1 mmol/l versus lispro 3.5 ± 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 ± 0.1 mmol/l). For blood glucose t_min was 59.3 ± 3.4 min in the aspart and 63.5 ± 5.3 min in the lispro group (ns). After 40 min a lower C-peptide was determined for aspart (225 ± 21 pmol/l versus lispro 309 ± 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 ± 21 pmol/l versus aspart 105 ± 18 pmol/l). The maximal concentration of insulin was detected in both groups after 40 min (lispro 20.8 ± 1.1 mU/l versus aspart 24.6 ± 1.3 mU/l; p = 0.032). For insulin t_max was 33.0 ± 2.6 min in the aspart versus 33.3 ± 2.6 min in the lispro group (ns). The present results indicate a more rapid absorption of insulin aspart in comparison to insulin lispro. Higher insulin concentrations after subcutaneus injection may be advantageous in meal-related treatment of diabetes.

References

• 1 Andersen L, Jørgensen P N, Jensen L B, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence and pharmacokinetic studies.  Clin Biochem. 2000;  33 627-633
  PubMedGoogle Scholar
• 2 Barnett A H, Owens D R. Insulin analogues.  Lancet. 1997;  349 47-51
  CrossrefPubMedGoogle Scholar
• 3 Bhaskar R, Chou M CY, Field J B. Time-action characteristics of regular and NPH insulin in insulin treated diabetics.  J Clin Endocrinol Metab. 1980;  50 475-479
  PubMedGoogle Scholar
• 4 Bolli G B, Di Marchi R D, Park G D, Pramming S, Koivisto V A. Insulin analogues and their potential in the management of diabetes mellitus.  Diabetologia. 1999;  42 1151-1167
  CrossrefPubMedGoogle Scholar
• 5 Hedman C A, Lindstrom T, Arnqvist H J. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes.  Diabetes Care. 24 ((Letter)) 2001;  1120-1121
  PubMedGoogle Scholar
• 6 Home P D, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.  Eur J Clin Pharmacol. 1999;  55 199-203
  CrossrefPubMedGoogle Scholar
• 7 Home P D, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.  Diabet Med. 2000;  17 762-770
  CrossrefPubMedGoogle Scholar
• 8 Howey D C, Bowsher R R, Brunelle R L, Woodworth J R. [Lys(B28), Pro(B29)]-human insulin - A rapidly absorbed analogue of human insulin.  Diabetes. 1994;  43 396-402
  CrossrefPubMedGoogle Scholar
• 9 Kang S, Creagh F, Peters J R, Brange J, Völund A, Owens D R. Comparison of subcutaneous soluble human insulin and insulin analogues (Asp^B9, Glu^B27, Asp^B10, Asp^B28) on meal-related plasma glucose excursions in type 1 diabetic subjects.  Diabetes Care. 1991;  14 571-577
  CrossrefPubMedGoogle Scholar
• 10 Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini M G, Bartocci L, Brunetti P, Bolli G B. Long-term intensive treatment of type I diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime.  Diabetes Care. 1999;  22 468-477
  PubMedGoogle Scholar
• 11 Mudaliar S R, Lindberg F A, Joyce M, Beerdsen P, Strange P, Lin A, Henry R R. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.  Diabetes Care. 1999;  22 1501-1506
  CrossrefPubMedGoogle Scholar
• 12 Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari A M, Paolisso G, Marfella R, Giugliano D. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.  J Am Coll Cardiol. 2002;  39 1145-1150
  CrossrefPubMedGoogle Scholar
• 13 Raskin P, Guthrie R A, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.  Diabetes Care. 2000;  23 583-588
  PubMedGoogle Scholar
• 14 World Medical Association declaration of Helsinki . Recommendations guiding physicians in biomedical research involving human subjects.  JAMA. 1997;  277 925-926
  CrossrefPubMedGoogle Scholar
• 15 Zinman B. The physiological replacement of insulin: an elusive goal.  New Engl J Med. 1989;  321 367-370
  PubMedGoogle Scholar
• 16 Zinman B, Tildesley H, Chiasson J L, Tsui E, Strack T. Insulin lispro in CSII. Results of a double-blind cross-over study.  Diabetes. 1997;  46 440-443
  CrossrefPubMedGoogle Scholar

M.D. Marc-Alexander von Mach

II. Medical Department

University Hospitals

Langenbeckstrasse 1

55131 Mainz

Germany

Phone: + 49-6131-174154

Fax: + 49-6131-232468

Email: marcm@giftinfo.uni-mainz.de